PAREXEL and Eli Lilly and Co. have entered a collaboration to launch a clinical research learning and development program in China. The program aims to bring high-value training opportunities to China’s clinical trial sites and investigators to enhance the execution of local clinical trials.   To encourage innovation in drug development, the Chinese government recently released a series of new policies for clinical research, resulting in a sharp increase in the number of clinical trials in Chi...